Department of Neurosurgery, University Hospital of Ioannina, Ioannina, Greece.
Mol Imaging Biol. 2011 Apr;13(2):348-51. doi: 10.1007/s11307-010-0369-y.
Multidrug resistance (MDR) remains a major obstacle to successful chemotherapeutic treatment of cancer. Several chemotherapeutic and radiopharmaceutical agents are substrates of the pumps encoded by the MDR genes, and therefore, their accumulation is prevented. We evaluated in vivo whether [(99m)Tc]tetrofosmin ((99m)Tc-TF) uptake is influenced by the MDR profile of gliomas.
Eighteen patients with histologically confirmed glioma were included in the study. Brain single-photon emission computed tomography by (99m)Tc-TF was performed within a week prior to surgical excision, and the expression of MRP5 was assessed by immunohistochemistry. Radiotracer accumulation was assessed by a semiquantitative method, calculating the lesion-to-normal uptake ratio.
Using Spearman's ρ analysis, we found no correlation between tracer uptake expressed as lesion-to-normal and MRP5 expression. There was a significant correlation between glioma aggressiveness as assessed by Ki-67/MIB-1 and MRP5 expression.
The present data suggest that (99m)Tc-TF uptake is not influenced by glioma's MDR phenotype. Thus, (99m)Tc-TF constitutes a suitable radiotracer for imaging gliomas.
多药耐药（MDR）仍然是癌症化疗成功的主要障碍。几种化疗药物和放射药物是由 MDR 基因编码的泵的底物，因此，它们的积累被阻止了。我们评估了 [(99m)Tc]四氮茂 [(99m)Tc-TF]摄取是否受胶质瘤 MDR 特征的影响。
18 名经组织学证实患有胶质瘤的患者被纳入研究。在手术切除前一周内进行脑单光子发射计算机断层扫描 (SPECT) 检查 [(99m)Tc-TF]，并用免疫组织化学评估 MRP5 的表达。通过半定量方法评估示踪剂摄取，计算病变与正常摄取的比值。
通过 Spearman's ρ 分析，我们发现示踪剂摄取与 MRP5 表达之间没有相关性。Ki-67/MIB-1 评估的胶质瘤侵袭性与 MRP5 表达之间存在显著相关性。
目前的数据表明，[(99m)Tc-TF]摄取不受胶质瘤 MDR 表型的影响。因此，[(99m)Tc-TF] 是一种适合成像胶质瘤的放射性示踪剂。
Zotero 插件